• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

NYC Rectal Cancer Trial Delivers ‘Unheard-of' Result: Complete Remission for Everyone (trial size = 12)

Shiloh

Editor, Senior Moderator
Source: https://www.nbcnewyork.com/news/hea...sult-complete-remission-for-everyone/3721476/

NYC Cancer Trial Delivers ‘Unheard-of' Result: Complete Remission for Everyone
Patients with a particular kind of cancer and a particular kind of mutation received a new therapy called dostarlimab and had results not seen in a cancer trial before
Published June 6, 2022 • Updated 35 mins ago

A small NYC-led cancer trial has achieved a result reportedly never before seen - the total remission of cancer in all of its patients.

To be sure, the trial — led by doctors at Memorial Sloan Kettering and backed by drug maker GlaxoSmithKline — has only completed treatment of 12 patients, with a specific cancer in its early stages and with a rare mutation as well.

But the results, reported Sunday in the New England Journal of Medicine and the New York Times, were still striking enough to prompt multiple physicians to tell the paper they were believed to be unprecedented.

One cancer specialist told the Times it was an "unheard-of" result.

According to the NEJM paper and the Times report, all 12 patients had rectal cancer that had not spread beyond the local area, and their tumors all exhibited a mutation affecting the ability of cells to repair damage to DNA...
 
Amazing results!

At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.
 
Fantastic!....sample size small at 12 but hopefully this result will bear out in a larger trial.

Please people, do your cancer screenings....there are so many effective treatments now.....
 
Back
Top